BTN3A3 and prostate disorder: Under Bonferroni correction (P < 0.05/525 = 9.5 × 10-5), an increase in CCM levels was associated with a reduced risk of colorectal malignancy, while BTN3A3 exhibited associations with multiple diseases, including hyperplasia of prostate, unspecified hematuria, inguinal hernia, and hypothyroidism(Supplementary Tables S11-21).